Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS

Next Previous
Trial Profile

A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Futibatinib (Primary)
  • Indications Biliary cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Taiho Pharmaceutical

    • Most Recent Events

    • 01 Feb 2023 Results (n=83) assessing safety and efficacy of futibatinib in Japanese patients with advanced solid tumors, published in the Cancer Science.
    • 21 Sep 2021 Results (n=44; as of 26 Nov 2020) presented at the 46th European Society for Medical Oncology Congress.
    • 13 Sep 2021 According to a Taiho Oncology media release, result of pooled analysis from this study assessing safety profile of futibatinib and initial results from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2021. Results will be shared as a poster presentation on September 16, 2021. The abstract for this presentation is available on the ESMO website
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top